Study Details

Back to Search Results

A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients with Type 2 Diabetes and Chronic Kidney Disease

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02358096

Astellas Study ID

The unique identification code given by the study sponsor.

8232-CL-0004

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2014-002349-23

Follow Trial

Condition

Kidney Disease, Adult Onset Diabetes

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 years - 85 years

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Mar 2015 - Mar 2017

Masking

Triple (Participant, Investigator, Outcomes Assessor)

Enrollment number

125

A Phase 2, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients with Type 2 Diabetes and Chronic Kidney Disease

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients with Type 2 Diabetes and Chronic Kidney Disease? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site ES34004

Barcelona, Spain, 08035

Site PL48006

Rzeszow, Poland, 35-055

Site DK45006

Viborg, Denmark, 8800

Site GB44005

London, United Kingdom, SE1 9RT

Site ES34005

Barcelona, Spain, 08025

Site IT39005

Pavia, Italy, 27100

Site ES34001

Barcelona, Spain, 08003

Site CZ42002

Brno, Czech Republic

Site ES34006

Lugo, Spain, 27880

Site DE49002

Düsseldorf, Germany, 40210

Site PL48004

Lodz, Poland, 94-225

Site CZ42003

Ceské Budejovice, Czech Republic, 370 01

Site PL48003

Plock, Poland, 09-402

Site HU36017

Szekesfehervar, Hungary, 8000

Site DK45004

Gentofte, Denmark, 2820

Site PL48008

Lodz, Poland, 94-048

Site IT39012

Rome, Italy, 00189

Site IT39004

Turin, Italy, 10141

Site BE32004

Roeselare, Belgium, 8800

Site CZ42005

Praha 10, Czech Republic, 108 00

Site HU36003

Hatvan, Hungary, H-3000

Site HU36010

Budapest, Hungary, H-1096

Site ES34002

Barcelona, Spain, 08907

Site HU36018

Veszprem, Hungary, H- 8200

Site HU36012

Kaposvar, Hungary, 7400

Site GB44004

Burton-on-Trent, United Kingdom, DE13 0RB

Site CZ42001

Prague 4, Czech Republic, 140 21

Site GB44001

Chester, United Kingdom, CH2 1UL

Site NL31002

Eindhoven, Netherlands, 5631 BM

Site DK45001

Herlev, Denmark, 2730

Site IT39007

Bergamo, Italy, 24127

Site DK45003

Frederiksberg, Denmark, 2000

Site DE49008

Elsterwerda, Germany, 04910

Site HU36016

Budapest, Hungary, 1036

Site ES34003

PALMA DE MALLORCA, Spain, 7120

Site GB44003

South Yorkshire, United Kingdom, DN2 5LT

Site PL48005

Sopot, Poland

Site BE32002

Brussels, Belgium, 1070

Site DE49007

Bosenheim, Germany, 55545

Site PL48028

Kraków, Poland, 30-069

Site PL48027

Oświęcim, Poland, 32-600

Site HU36005

Szikszó, Hungary

Site DE49003

Heidelberg, Germany, 69115

Site DE49004

Berlin, Germany, 13125

Site DK45002

Hillerød, Denmark, 3400

Site DK45016

Copenhagen, Denmark, 2400

Site NL31001

Dordrecht, Netherlands, 3318 AT

Site PL48022

Radom, Poland, 26-600

Site IT39002

Piacenza, Italy, 29100

Site PL48001

Poznan, Poland, 61655

Site DK45007

Holsterbro, Denmark, 7500

Site HU36002

Balatonfüred, Hungary, 8230

Site CZ42004

Praha 9, Czech Republic, 190 00

Site ES34012

Madrid, Spain, 28041

Site DE49006

Berlin, Germany, 13353

Site ES34010

Majadahonda, Spain, 28222

Site ES34007

Ciudad Real, Spain, 13005

Site PL48026

Lodz, Poland, 90-302

Site NL31004

Rotterdam, Netherlands, 3045 PM

Site ES34008

Madrid, Spain, 28007

Site PL48025

Warszawa, Poland, 00-660

Site NL31003

Hoogeveen, Netherlands, 7909 AA

Site BE32001

Brussels, Belgium, 1090

Site HU36007

Szigetvar, Hungary, 7900

Site PL48002

Torun, Poland, 87-100

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo